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Background: The hypertensive, pro-inflammatory, obese state is strongly coupled to peripheral and hepatic insulin
resistance (in composite termed metabolic syndrome [MS]). Hepatic pro-inflammatory pathways have been
demonstrated to initiate or exacerbate hepatic insulin resistance and contribute to fatty liver, a correlate of MS.
Previous studies in seasonally obese animals have implicated an important role for circadian phase-dependent
increases in hypothalamic dopaminergic tone in the maintenance of the lean, insulin sensitive condition.
However, mechanisms driving this dopaminergic effect have not been fully delineated and the impact of
such dopaminergic function upon the above mentioned parameters of MS, particularly upon key intra-hepatic
regulators of liver inflammation and lipid and glucose metabolism have never been investigated.
Objective: This study therefore investigated the effects of timed daily administration of bromocriptine, a potent
dopamine D2 receptor agonist, on a) ventromedial hypothalamic catecholamine activity, b) MS and c) hepatic protein
levels of key regulators of liver inflammation and glucose and lipid metabolism in a non-seasonal model of MS - the
hypertensive, obese SHR rat.
Methods: Sixteen week old SHR rats maintained on 14 hour daily photoperiods were treated daily for 16 days with
bromocriptine (10 mg/kg, i.p.) or vehicle at 1 hour before light offset and, subsequent to blood pressure recordings on
day 14, were then utilized for in vivo microdialysis of ventromedial hypothalamic catecholamine activity or sacrificed
for the analyses of MS factors and regulators of hepatic metabolism. Normal Wistar rats served as wild-type controls for
hypothalamic activity, body fat levels, and insulin sensitivity.
Results: Bromocriptine treatment significantly reduced ventromedial hypothalamic norepinephrine and serotonin
levels to the normal range and systolic and diastolic blood pressures, retroperitoneal body fat level, plasma insulin and
glucose levels and HOMA-IR relative to vehicle treated SHR controls. Such treatment also reduced plasma levels of
C-reactive protein, leptin, and norepinephrine and increased that of plasma adiponectin significantly relative to SHR
controls. Finally, bromocriptine treatment significantly reduced hepatic levels of several pro-inflammatory pathway
proteins and of the master transcriptional activators of lipogenesis, gluconeogenesis, and free fatty acid oxidation
versus control SHR rats.
Conclusion: These findings indicate that in SHR rats, timed daily dopamine agonist treatment improves hypothalamic
and neuroendocrine pathologies associated with MS and such neuroendocrine events are coupled to a transformation
of liver metabolism potentiating a reduction of elevated lipogenic and gluconeogenic capacity. This liver effect may
be driven in part by concurrent reductions in hyperinsulinemia and sympathetic tone as well as by reductions in
intra-hepatic inflammation.
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Many vertebrate species in the wild exhibit annual cycles
of metabolism, oscillating between seasons of obese, in-
sulin resistance and lean, insulin sensitivity (reviewed in
[1,2]. The ability to anticipate a season of low food avail-
ability by the endogenous induction of the obese, insulin
resistant state supports survival during such a subsequent
season when food availability is scarce. During the obese,
insulin resistant season, in the absence of ample carbohy-
drate in the environment, increased hepatic glucose out-
put supports brain function while fat stores are utilized in
insulin resistant peripheral tissues thereby sparing plasma
glucose for utilization by the brain, which has a near
absolute requirement for glucose as a fuel. The circadian
rhythm of dopamine release at the region of the biological
clock, the hypothalamic suprachiasmatic nuclei (SCN),
has been implicated in the regulation of peripheral insulin
sensitivity and glucose and lipid metabolism in such sea-
sonal mammals (reviewed in [1,2]). The circadian peak of
dopamine release at the region of the SCN in seasonal
insulin sensitive animals is absent in seasonal insulin re-
sistant animals [3] and ablation of this dopaminergic
activity by SCN area site-specific neurotoxin application
in seasonal or nonseasonal insulin sensitive animals in-
duces a marked insulin resistant state [4]. Moreover, intra-
peritoneal or intracerebroventricular administration of
bromocriptine, a potent dopamine D2 receptor agonist, to
seasonal insulin resistant animals reverses the insulin
resistance/glucose intolerance [5-7]. Such bromocriptine
treatment has been demonstrated to reduce both hepatic
glucose and lipid production and secretion in seasonal
insulin resistant animals [6,8-10]. Other studies have
identified the ventromedial hypothalamus as an additional
target for such metabolic influences of hypothalamic dopa-
minergic activity (potentially in concert with or resulting
from such activity at the region of the SCN). Bromocrip-
tine treatment of seasonal animals reduces elevated ventro-
medial hypothalamus (VMH) norepinephrine (NE) and
serotonin (S) neuronal activities [2] that are characteristic
of the insulin resistant state across a variety of animal
models of the condition [1] and that can induce the obese,
insulin resistant condition in normal animals (via VMH
NE and S infusion) through their regulation of the neuro-
endocrine axis (e.g., simultaneous increase in sympathetic
tone, plasma insulin, glucagon and norepinephrine among
other factors) without alteration of the diet [1,11,12].
However, we are still searching for insights into how
these (hypothalamic or other) influences of bromocrip-
tine affect regulatory biochemical pathways in liver that
facilitate/mediate these simultaneous bromocriptine ef-
fects on glucose and lipid metabolism therein and system-
ically. Also, it is not known whether such bromocriptine
effects on VMH neurochemistry are specific to seasonal
animals or are a fundamental-general phenomenon of theinsulin resistant state among mammals, across seasonal
and non-seasonal animal models of insulin resistance
alike. Moreover, the potential impact of bromocriptine
treatment not merely on insulin resistance but rather
upon the MS (insulin resistance, obesity, dyslipidemia,
hypertension, and hepatic inflammation) has not been
fully investigated. This study therefore investigated the im-
pact of bromocriptine treatment in the hypertensive, insu-
lin resistant SHR rat on a) VMH neurochemistry known
to regulate peripheral (hepatic) glucose and lipid metabol-
ism, b) the broader malaise of MS (hypertension, obesity,
fatty liver, hyperinsulinemia, insulin resistance, and pro-
inflammatory state) that contribute to cardiometabolic
risk and c) liver biochemical pathways operative in the
(dys)regulation of hepatic glucose and lipid production,
namely transcription factor or enzyme proteins modulat-
ing proinflammatory (SOCS3, NFκB, IKK, JNK), gluco-
neogenic (FOXO1-Ser256, PEPCK, G6Pase, PGC-1α) fatty
acid oxidative (PGC-1α, PPARα), and lipogenic (SREBP-1,
mTORC, PGC-1β, PPARγ) activities. Here we show that
dopamine agonist treatment with bromocriptine at the
onset of locomotor activity in SHR rats normalizes ele-
vated levels of VMH noradrenergic and serotonergic
activities associated with and known to induce insulin
resistance and fattening in seasonal rodents. Such treat-
ment also reduces hypertension, insulin resistance, fatty
liver and several key hepatic transcription factors that
induce hepatic pro-inflammatory pathways, gluconeo-
genesis and lipogenesis. The bromocriptine-induced
reduction in hypertension is associated with and may
be potentiated by its induced changes in VMH activity
and reduced sympathetic tone. The bromocriptine-induced
reduction in liver and adipose fat content is associ-
ated with and may derive in part from reductions of
hyperinsulinemia, liver lipogenic responsiveness to in-
sulin and pro-inflammatory pathways that potentiate
lipogenic activity. The reduction in bromocriptine-
induced insulin resistance is coupled to and may de-
rive in part from reductions in hepatic transcription




Male spontaneously hypertensive rats (SHR) and Wistar
rats (Taconic, Hudson, NY) were housed individually
and habituated to our climate-controlled animal care fa-
cility (14 hour daily photoperiods, light onset at 05:00)
for at least 14 days before initiation of any experimen-
tation. They were allowed to feed (Standard lab chow
18.6% protein, 44.2% carbohydrate, and 6.2% fat rodent
diet 2018, Harlan, NY) and drink ad libitum throughout
the study period. At the initiation of experimentation, ani-
mals were 16 weeks of age and at an average body weight
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severely hypertensive [13].
Experimental design
Two separate investigations were conducted in this
study. In the initial investigation, we tested for possible
differences between hypertensive SHR versus normal
Wistar rats in extracellular monoamine (dopamine, sero-
tonin, and norepinephrine) metabolites (measure of neuro-
transmitter release level) in the VMH that are known to be
strongly involved in the regulation of insulin sensitivity,
liver glucose output, plasma lipid level and body fat store
level in rodents [1,11,12,14]. This investigation also exam-
ined the potential impact of chronic bromocriptine admin-
istration upon these VMH monoamine profiles in SHR
rats. In vivo microdialysis was employed to study daily
extracellular profiles of monoamine metabolites in the
VMH of SHRs treated with bromocriptine (10 mg/kg/day)
(N = 8) or vehicle (N = 8) and vehicle treated, age-matched
normotensive Wistar rats (N = 6) (administered at 13 hours
after light onset [HALO]) for 14 days. Microdialysis sam-
ples from the VMH of free living rats held under a daily
photoperiod and allowed to feed and drink ad libitum dur-
ing the sampling were collected every 2 hours continu-
ously over a 24 hour period. Microdialysis samples were
assayed via HPLC for the metabolites of dopamine (homo-
vanillic acid, HVA), serotonin (5-hydroxy-indoleacetic
acid, 5HIAA), and norepinephrine (3-methoxy-4-hydroxy-
phenylglycol, MHPG) as previously described [14].
In the second investigation, SHR rats were randomized
to one of two treatment groups: bromocriptine (10 mg/
kg/day) (N = 8) or vehicle (30% ethanol, USP) (N = 8) ad-
ministered intraperitoneally at 13 HALO (a time of peak
dopamine release at the area of the SCN clock in noctur-
nal rodents [4]) daily for 16 days. A group of Wistar rats
served as the wild-type control for lipid, insulin resist-
ance, and blood pressure measures. Measurements of
blood pressure were taken at 4 hours after light onset on
the day before treatment initiation and again 14 days
after treatment (15 hours after the final bromocriptine in-
jection). Animals were sacrificed on day 16 of the study at
4 HALO, the peak time of daily fasting in these nocturnal
animals, and blood samples were collected for analyses of
humoral metabolic and immune factors, including plasma
insulin, glucose, leptin, adiponectin, norepinephrine, and
C-reactive protein (CRP). Retroperitoneal fat pads were re-
moved and weighed as an index of body fat store level and
livers were quickly removed and frozen for quantitative
analyses of proteins regulating inflammation ([nuclear fac-
tor kappa-light-chain-enhancer of activated B cells; NfκB],
[IκB kinase; IKKαβ], [c-Jun N-terminal kinase; JNK],
[suppressor of cytokine signaling; SOCS3]), gluconeogene-
sis ([peroxisome proliferator-activated receptor gamma
coactivator-1α; PGC1α], [Forkhead box protein O1;FOXO1], [Glucose 6-phosphatase; G6Pase], [Phosphoenol-
pyruvate carboxykinase; PEPCK]), lipogenesis ([peroxi-
some proliferator-activated receptor gamma coactivator-1
beta; PGC1β], [sterol regulatory element-binding protein 1;
SREBP1], [mammalian target of rapamycin complex 1;
mTORC1], [peroxisome proliferator-activated receptor;
PPARγ]), and fatty acid oxidation (PGC1α and PPARα), and
for Total liver lipid content. Daily food consumption and
body weight changes were monitored periodically over the
course of the study. All animal experiments were conducted
according to the protocols approved by the Institutional Ani-
mal Care and Use Committee of VeroScience, LLC.
Blood pressure (BP) measurements
Systolic and diastolic blood pressure was measured
on conscious animals with a tail-cuff Volume Pressure
Recording method (CODA-6 non-invasive blood pressure
system, Kent Scientific Corp. Torrington, CT) following
manufacturer’s instructions. Several days before experi-
mental recordings, rats were acclimated to the restraining
cage and the tail cuff to minimize or reduce any stress in-
fluence on the readings. BP measurements were performed
before and after 14 days of treatment. BP values per animal
were the result of an average of 6-8 measurements.
Surgery
After a two week adaptation to the facility, each rat in
the microdialysis study was anesthetized with a mixture
of ketamine and xylazine (80:60 mg/kg body weight, i.p.)
and placed on a stereotaxic apparatus (David Kopf). A 30-
gauge stainless steel guide cannula (Carnegie Medicine,
Stockholm, Sweden) was permanently implanted aimed at
the top of the VMH [15] at coordinates: 2.8 mm posterior
to bregma, 0.7 mm right lateral to the midsagittal suture,
and 9.0 mm ventral to the surface of the dura with the in-
cisor bar set 1 mm below the interaural line. The cannula
was secured permanently to the skull with three stainless
steel screws penetrating the skull and acrylic cement.
Microdialysis
During the entire microdialysis procedure, each animal was
placed in an acrylic bowl with free access to food and water
and was maintained on a 14-h daily photoperiod (light onset
05:00 am). A 32-gauge dialysis probe with a 1-mm-long tip of
semi-permeable membrane (20,000 molecular weight cutoff)
was inserted into the guide cannula and the probe membrane
was placed in the VMH at 9.0-10.0 mm with respect to the
dura. Using a microinjection pump (Carnegie Medicine,
CMA/100), filtered Ringer’s solution (147 mMNaCl, 3.4 mM
CaCl2, 4.0 mM KCl, pH 6.0) was continuously perfused
through the probe at a rate of 0.12μl/min. The probewas con-
nected to the microinjection pump by microbore Teflon tub-
ing through a counterbalanced 2-channel liquid swivel arm
(Bioanalytical Systems, West Lafayette, IN) attached to the
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without the tubing becoming tangled during the experi-
mental period. Rats were put in the bowl and attached to
the microdialysis device at 10:00 hours (5 HALO) on the
test day following 16 days of treatment and sample collec-
tion subsequently began at 5 hours after light onset. Mi-
crodialysis samples were collected into 300 μl vials
(containing 2 μl of 0.1 N perchloric acid solution) at 2-
hour intervals continuously for 24 hours through an auto-
mated refrigerated fraction collector (modified CMA/170,
CMA/Microdialysis, Acton, MA, USA). Bromocriptine or
vehicle was given 1 hour before light offset daily for 14 days
including on the day of microdialysis.
Analysis of microdialysis samples
The dialysis samples were analyzed by high-performance
liquid chromatography with electrochemical detection
(HPLC-EC with radial-flow cell; Bioanalytical System
BAS 200). A 5 μl dialysate sample was injected into the
system by an autosampler (Bioanalytical System Sample
sentinel). The column used was a 100 × 2 mm reverse
phase Octadecyl-silica ODS with 3 μm particle packing
(BAS Unijet LC Column). The mobile phase contained
0.1 M monochloroacetic acid, 1.0 mM sodium octyl sul-
fate, 0.7 mM EDTA, 10 mM NaCl, and 2% (v/v) aceto-
nitrile, adjusted to pH 3.1. The mobile phase was filtered
and degassed before use, and delivered at a flow rate of
400 μl/min. A glassy carbon detector electrode (UniJet™
Amperometric Detector; BAS) was used for detection
with an electrode oxidation potential of 0.65 V. Detector
output was recorded on a computer. Peak integration
and quantitation were performed via computerized soft-
ware using an external standard for calibration. Stan-
dards were prepared in 0.1 N perchloric acid. Each of
5-HIAA, MHPG and HVA contents in the dialysate were
determined. Results are reported as pg amine metabolite
per 5 μl of dialysate.
Assay of blood samples and analysis of liver lipid content
Blood glucose concentrations were determined by a
blood glucose monitor (OneTouch Ultra, LifeScan, Inc,
Milpitas, California). Plasma insulin, leptin, adiponectin,
norepinephrine, and C-reactive protein (CRP) were
assayed by EIA using commercially available assay kits
utilizing anti-rat serum and rat insulin, leptin adiponectin,
and CRP as standards (ALPCO Diagnostics, Salem, NH).
Liver tissue was homogenized in 5% NP-40, heated,
centrifuged, and supernatant assayed for triglyceride con-
tent by Triglyceride Determination Kit (Sigma-Aldrich, St.
Louis, MO).
Western blot analyses
Liver proteins were quantified by western blot analysis
as follows using BioRad, (Hercules, CA) Criterion andChemiDoc systems following manufacturers’ instructions.
PGC1α antibody was purchased from EMD Millipore,
Billerica, MA, Cat# ST1202. All other antibodies pur-
chased from Santa Cruz Biotechnology, Santa Cruz, CA
were as follows: FOXO1Ser256 Cat# sc-101681; G6Pase-α
Cat# sc-27198; PEPCK Cat# sc-32879; PPARα Cat# sc-
9000; SREBP-1 Cat# sc-13551; mTORC Cat# sc-8319;
PPARγ Cat# sc-7273; PGC1β Cat# sc-67286, NFκB p65
Cat# sc-8008; IKKαβ Cat# sc-7607; SOCS3 Cat# sc-9023;
JNK Cat# sc-571; Actin Cat# sc-47778. Criterion gradient
tris-glycine precast gels, secondary antibodies, PVDF blot-
ting membranes, molecular weight markers, and Enhanced
Chemiluminescence (ECL) reagents were also pur-
chased from BioRad. Samples from 8 SHR Vehicle, 8 SHR
Bromocriptine treated rats, and 6 Wistar wild type con-
trols were loaded onto the same 26 well Criterion gel
along with the molecular weight markers; band intensity
was compared only within the samples loaded onto the
same gel. A housekeeping protein (actin) was concur-
rently quantified on all gels, and the test protein amount
was normalized to actin in the Western blot analysis.
Protein bands were quantified with BioRad ImageLab
4.1 software.
Results
Effect of SHR vs Wistar background and of Bromocriptine
in SHR rats on Daily VMH Extracellular Monoamine
Metabolite Profiles.
Figure 1A shows the 22 hour pattern of extracellular
MHPG in the VMH of freely moving SHR rats treated with
either bromocriptine or vehicle for 14 days compared to
that of normotensive Wistar controls. A two-way ANOVA
with repeated measures revealed a significant main effect
of the bromocriptine treatment (F10, 80 = 2.340, P < 0.05).
SHR rats exhibited elevated VMH NE release relative to
Wistar normal controls (66% increase, P < 0.0001). How-
ever, timed daily bromocriptine administration signifi-
cantly reduced VMH MHPG of SHR rats compared with
vehicle treated SHR rats (65%, P < 0.0001).
Figure 1B shows the 22 hour pattern of extracellular
HVA in the VMH of freely moving SHR rats treated with
either bromocriptine or vehicle for 14 days compared to
that of normotensive Wistar controls. A two-way ANOVA
with repeated measures revealed a significant strain treat-
ment effect (F2, 80 = 10.069, P < 0.005) and a significant
interaction effect between treatment and time of day
(F20, 80 = 1.99, P < 0.02). SHR rats had significantly lower
extracellular VMH HVA content compared with normal
Wistar rats (29%, P < 0.001). However, extracellular VMH
HVA content was not different between BC and vehicle
treated SHR rats.
Figure 1C shows the 22 hour pattern of extracellular
5-HIAA in the VMH of freely living SHR rats treated with
either bromocriptine or vehicle for 14 days compared to
Figure 1 Effect of timed daily bromocriptine administration on
ventromedial hypothalamic catecholamines. A. SHR rats exhibited
elevated VMH NE release relative to Wistar normal controls
(P < 0.0001). Timed daily bromocriptine administration significantly
reduced VMH MHPG of SHR rats compared with vehicle treated
SHR rats (P < 0.0001). B. SHR rats exhibited significantly lower
extracellular VMH HVA content compared with normal Wistar
rats (p < 0.001). C. SHR rats exhibited elevated VMH 5-HIAA
release relative to Wistar normal controls (P < 0.0001). Timed daily
bromocriptine administration significantly reduced VMH 5-HIAA of SHR
rats compared with vehicle treated SHR rats (P < 0.0001) There was no
significant difference in VMH 5-HIAA levels between SHR BC treated
and Wistar rats.
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fect of the interaction between treatment and time of day
(F20, 80 = 2.555, P < 0.002) by a two-way ANOVA with re-
peated measures. Post-hoc multiple-range test revealed a
significant group difference on VMH 5-HIAA levels be-
tween SHR vehicle treated and BC treated (49% reduction
by BC treatment; P < 0.0001) as well as between SHR
and Wistar vehicle treated rats (53% reduction in
Wistars; P < 0.0001). There was however, no significant
difference on VMH 5-HIAA levels between SHR BC
treated and Wistar rats.Effects of bromocriptine on metabolic and
neuroendocrine factors potentiating metabolic
syndrome
Timed daily bromocriptine treatment for 14 days signifi-
cantly reduced retroperitoneal fat pad weight of SHR
rats by 42% (P < 0.0001), body weight and average daily
food consumption slightly over the 14 day treatment
period relative to vehicle treated controls (Figure 2). Such
bromocriptine treatment also significantly reduced liver
lipid content by 28% (P = 0.01). Bromocriptine treat-
ment also reduced systolic blood pressure from 230 ±
6 mmHg to 188 ± 6 mmHg (P = 0.0003) and diastolic
blood pressure from 185 ± 11 mmHg to 130 ± 8 mm
Hg (P = 0.001) towards the values observed in wild
type Wistar rats (Figure 3).
Bromocriptine treatment reduced plasma glucose
concentrations by 12% (from 112 ± 3 to 99 ± 5 mg/dl,
P = 0.03), and plasma insulin by 55% from 6.9 ± 1.0 to
3.1 ± 0.5 ng/ml (P = 0.007), resulting in a reduction in
the homeostasis model assessment of insulin resistance
(HOMA-IR) by 60% (from 47 to 18 μU/ml*mmol/L, P =
0.004) relative to vehicle controls towards the values ob-
served in wild type Wistar rats (Figure 4). Bromocriptine
treatment produced significant reductions in plasma lep-
tin by 62% (from 971 ± 83 to 374 ± 41 pg/ml, P < 0.0001),
plasma norepinephrine by 41% (from 906 ± 117 to 538 ±
69 pg/ml, P < 0.02), and CRP by 15% (from 472 ± 15 to
402 ± 29 mg/l, P < 0.05) levels, while it increased plasma
adiponectin levels by 14% (from 10.4 ± 0.5 to 11.8 ±
0.3 ng/ml, P < 0.03) (Figure 5).
Effect of bromocriptine on liver pro-inflammatory,
gluconeogenic, fatty acid oxidative, and lipogenic
proteins
Bromocriptine treatment simultaneously reduced the
levels of the liver inflammatory pathway activating tran-
scription factor proteins NFκBp65, JNK, IKKαβ, and
SOCS3 by 16% (P = 0.03), 22% (P = 0.003), 24% (P =
0.004), and 38% (P < 0.0001), respectively relative to
control values (Figure 6). Such bromocriptine treat-
ment also reduced the levels of the hepatic gluconeo-
genic enzymes, PEPCK and G6Pase while increasing
the levels of inactivated ser256 phosphorylated FOXO1
(thereby reducing the stimulatory effect of FOXO1 on
gluconeogenesis), by 17% (P < 0.04), 25% (P < 0.01),
282% (P = 0.026), respectively (Figure 7). Bromocrip-
tine also reduced the hepatic levels of pro-FFA oxida-
tive transcription factors, PGC1α, PPARα and PPARγ
by 26% (P < 0.01), 14% (P < 0.02), and 22% (P = 0.06),
respectively (Figure 8). Bromocriptine also reduced the
levels of liver triglyceride synthesis promoting proteins
SREBP1, mTORC1, and PGC1β by 37%, (P < 0.001),
21% (P = 0.001), and 23% (P = 0.015), respectively, relative
to SHR control (Figure 9).
Figure 2 Impact of timed daily bromocriptine or vehicle administration on body weight (Panel A), retroperitoneal fat pad (Panel B),
food consumptions (Panel C) and liver triglycerides (Panel D). Values are means ± SEM of 8 animals in each group. *Difference is statistically
significant; P values are noted under each panel.
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This study is the first to demonstrate that dopamine agon-
ist treatment ameliorates both major central and periph-
eral components of MS as evidenced by a simultaneous
improvement in a range of neuroendocrine and meta-
bolic pathologies including hypertension, obesity, hypergly-
cemia, hyperinsulinemia, insulin resistance, hyperleptinemia,
increased liver lipid content, and hepatic pro-inflammatory
protein pathway activation. Available evidence suggests
that such wide spread influences on metabolism are largely
via the hypothalamic/neuroendocrine axis [1,2,10-12,14].
Intracerebroventricular (icv) administration of bromocrip-
tine to seasonal insulin resistant hamsters reduces body fat
store levels, hyperinsulinemia, insulin resistance, and glu-
cose intolerance. Information regarding the CNS targets
for such icv dopamine agonist-induced improvements in
seasonal insulin resistance indicates that modulation of
monoamine activity at the hypothalamic VMH is at least
one such CNS target [11,12,14] among others (reviewed in
[1]). Seasonal insulin resistance is associated with eleva-
tions in VMH NE and 5HT activities and importantly, in-
fusion of exogenous NE and 5HT to the VMH of seasonal
insulin sensitive animals to raise these monoamine levels
to those observed in seasonal insulin resistant animals
induces marked insulin resistance and beta cell dysfunc-
tion [12,15] and this event has also been observed in non-
seasonal animals as well [11]. Systemic bromocriptinetreatment normalizes these VMH monoamine dysfunc-
tions and insulin resistance in seasonal hamsters [14]. Also,
preliminary data indicate that this influence of bromocrip-
tine treatment to reduce insulin resistance can be largely
attenuated by concurrent infusion of NE into the VMH
(Cincotta, unpublished data). The present observations of
a) increased VMH NE and 5HT activities in hypertensive,
insulin resistant SHR versus normal Wistar rats and b)
concurrent reductions in these VMH monoamine activities
and amelioration of MS extend and corroborate these pre-
vious findings now in a non-seasonal, genetic model of MS
and suggest that such hypothalamic aberrations may be a
fundamental component of the neuroendocrine milieu
supporting induction of MS. Several other animal models
of insulin resistance including the ob/ob mouse, db/db
mouse, Zucker fatty rat, and offspring of malnourished or
insulin treated pregnant rats all exhibit increased norad-
renergic turnover within the VMH (reviewed in [1]).
Where and how bromocriptine is acting to produce
these VMH corrections in monoamine activities is un-
known, however sites involved may include at the VMH
itself, as well as at the area of and surrounding the SCN
[3,4] the biological circadian pacemaker for the organism
that communicates directly and indirectly (via the locus
coeruleus and nucleus tractus solitarius) with the VMH
and several other hypothalamic centers to regulate glu-
cose tolerance [1]. Diminished dopaminergic activity at
Figure 3 Impact of timed daily bromocriptine or vehicle administration on systolic (Panel A) and diastolic (Panel B) blood pressure.
Values are means ± SEM of 8 animals in each group. *Difference is statistically significant; P values are noted under each panel.
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sulin resistant state that is coupled with elevated VMH
NE and 5HT activity levels [3] and neurotoxic lesion of
dopaminergic neurons within this SCN area of insulin
sensitive animals induces seasonal insulin resistance [4].
Interestingly, the SHR rat is well characterized as having
reduced dopaminergic tone within the prefrontal cortex
and ventrolateral stiatum [16,17] and the current study
now indicates that such is also the case within the VMH
itself. We are currently investigating whether dopamin-
ergic activities at the SCN are also reduced in these SHR
rats as in seasonal insulin resistant states. We have ob-
served such reduced dopaminergic activity at the SCN
subsequent to high fat diet-induced insulin resistance [18].
Elevated VMH NE and 5HT activity produces a unique
neuroendocrine profile characterized by increased plasma
NE, epinephrine, glucagon, insulin, free fatty acid (FFA),
triglyceride, and leptin levels, increased sympathetic/
neuroendocrine drive for hepatic glucose output, adipose
lipolysis, and vasoconstriction [11], as well as an increased
insulin secretory response to glucose and hyperinsulinemia[11,15] that, as a composite, represents the hallmark of
the MS. This neuroendocrine profile in turn is coupled to
and/or potentiates insulin resistance, glucose intoler-
ance, hyperlipidemia, obesity (reviewed in detail in [1]
and hypertension [19]. Moreover, consistent with the ob-
served normalization in elevated VMH NE and 5HT activ-
ities in this study, plasma levels of insulin, glucose, leptin,
NE, and C-Reactive Protein were all reduced, and that of
adiponectin was elevated following bromocriptine treat-
ment in SHR rats. Furthermore, consistent as well with
these neuroendocrine changes, HOMA-IR calculations
indicate a marked improvement in insulin resistance fol-
lowing bromocriptine treatment. Additionally, plasma adi-
ponectin levels are inversely correlated with and protect
against both insulin resistance and fatty liver [20-22].
Likely due to decreased central (hypothalamic) dopa-
minergic tone as described above, SHR rats are hyper-
prolactinemic [23]. In turn, hyperprolactinemia has been
demonstrated to potentiate fattening and insulin resist-
ance in a variety of animal models and man (reviewed in
[2]; [24-29]). In this regard it is critical to appreciate that
Figure 4 Impact of timed daily bromocriptine or vehicle administration on plasma glucose (Panel A), plasma insulin (Panel B), and
HOMA-IR index (Panel C). Values are means ± SEM of 8 animals in each group. *Difference is statistically significant; P values are noted under
each panel.
Figure 5 Impact of timed daily bromocriptine or vehicle administration on humoral modulators of metabolism and inflammation – plasma
CRP (Panel A), plasma leptin (Panel B), plasma adiponectin (Panel C), and plasma norepinephrine (Panel D). Values are means ± SEM of
8 animals in each group. *Difference is statistically significant; P values are noted under each panel.
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Figure 6 Impact of timed daily bromocriptine or vehicle administration on pro-inflammatory regulators – NFκBp65 (Panel A), IKKαβ
(Panel B), SOCS3 (Panel C), and JNK (Panel D). Proteins we quantified by Western blotting. Values are means ± SEM of 8 animals in each
group. *Difference is statistically significant; P values are noted under each panel.
Figure 7 Impact of timed daily bromocriptine or vehicle administration on gluconeogenic pathway regulators – FOXO1 phosphorylated at
Ser256 (Panel A), glucose-6-phosphatase (Panel B), and PEPCK (Panel C). Proteins we quantified by Western blotting. Values are means ± SEM of
8 animals in each group. *Difference is statistically significant; P values are noted under each panel.
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Figure 8 Impact of timed daily bromocriptine or vehicle administration on fatty acid oxidation activators – PGC1α (Panel A), PPARα
(Panel B), and PPARγ (Panel C). Proteins we quantified by Western blotting. Values are means ± SEM of 8 animals in each group. *Difference is
statistically significant; P values are noted under each panel.
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lean, insulin sensitive versus obese, insulin resistant ani-
mals [2]. More importantly, a marked circadian rhythm
of metabolic responsiveness to prolactin exits in verte-
brates such that injections of prolactin into lean, insulin
sensitive animals at the time of day its level peaks in the
blood of obese, insulin resistant animals induces the
obese, insulin resistant state while injections of prolactin
into obese, insulin resistant animals at the time of day its
level peaks in the blood of lean, insulin sensitive animals
produces a lean, insulin sensitive condition (reviewed in
[2], [30,31]). Elevations of plasma prolactin levels can po-
tentiate MS via decreasing hypothalamic dopamine release
[32] thereby altering its signaling to the SCN to potentiate
MS as described herein and elsewhere [1] that includes in-
creasing lipogenic responsiveness to insulin in the periph-
ery [33-35]. In the present study, bromocriptine, which is
well known to effectively reduce hyperprolactinemia
[36,37], was administered daily just after the time of day
of the normal circadian peak in plasma prolactin levels
in lean, insulin sensitive rats [31] prior to the end of
the photoperiod to re-establish the normal dopaminergic
circadian input activity to the SCN. Such timed adminis-
tration would also likely function to re-establish a morenormal daily plasma prolactin profile as observed in insu-
lin sensitive rats [31], though such plasma prolactin levels
were not measured in this study. Consequently, the meta-
bolic effects of timed daily bromocriptine treatment ob-
served in this study may in part derive from a reduction of
plasma hyperprolactinemia and normalization of the daily
rhythm of plasma prolactin level towards that of lean, in-
sulin sensitive rats.
It should be noted that several studies have defined an
inhibitory effect of acute direct/autocrine/paracrine dopa-
mine on beta cell glucose stimulated insulin secretion
(GSIS) in animals and man [38-41], with a potential role
for gastrointestinal L-DOPA as an endogenous source for
such physiological beta cell dopamine responses that may
potentiate hyperglycemia [41]. Moreover, acute adminis-
tration of bromocriptine itself has been shown to produce
such an inhibitory effect on beta cell GSIS potentially via
noradrenergic α2 receptors [42]. While such observations
of acute direct dopamine activity to inhibit beta cell GSIS
and thereby potentiate hyperglycemia may seem at odds
with a multitude of observations indicating that circadian
timed chronic dopamine agonist therapy improves glucose
intolerance and hyperglycemia, a careful consideration
of the available evidence suggests a different scenario. In
Figure 9 Impact of timed daily bromocriptine or vehicle administration on lipogenesis regulators – SREBP1 (Panel A), mTORC (Panel B),
and PGC1β (Panel C). Proteins we quantified by Western blotting. Values are means ± SEM of 8 animals in each group. *Difference is statistically
significant; P values are noted under each panel.
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chronic systemic timed bromocriptine treatment, that re-
sets several hypothalamic circuits controlling metabolism
[3,4,10-12,14], reduces post glucose/meal challenge glu-
cose area under curve (AUC) and insulin AUC simultan-
eously [5,6,10,14,43,44]. Importantly, this effect in such
animals can be manifested with intracerebroventricular
administration of bromocriptine at nearly one thousandth
the effective systemic dose [10], and likely involves bromo-
criptine’s effect to reduce elevated VMH NE and S activ-
ities and Paraventricular nucleus (PVN) Neuropeptide Y
(NPY) and Corticotropin-releasing hormone (CRH) levels
(present study, [11,12,14,45], that potentiate insulin resist-
ance, direct hyperinsulinemia independent of insulin
resistance, and increased beta cell GSIS concurrently
[1,11,12,15]. However, in animals where glucose dysmeta-
bolism progresses from impaired glucose tolerance to dia-
betes with beta cell dysfunction, such chronic dopamine
agonist treatment reduces hyperglycemia while actually
improving (increasing) GSIS, including the beta cell re-
sponse to glucagon like peptide-1 [46,47].
A plausible biological organization worth investigat-
ing that may unify these findings is the possibility that cen-
tral (hypothalamic) circadian dopamine activities regulatebeta cell function and insulin sensitivity in a coordinated
fashion that would include regulation of paracrine dopa-
mine activity at the beta cell. Under this postulate, in insu-
lin resistant states, low hypothalamic dopamine activity
allows for (potentiates) 1) an altered beta cell response to
external (e.g., autonomic) stimuli that facilitates hyperin-
sulinemia and increased GSIS, as previous studies indicate
[15], that may include low paracrine beta cell dopamine
activity and 2) neuroendocrine mechanisms (as described
in this study) facilitating insulin resistance to thereby
establish a coordinated and controlled steady state
hyperinsulinemic, insulin resistant condition (as ob-
served in seasonal animals in the wild). Contrariwise,
with appropriate circadian time increased hypothal-
amic dopaminergic activity, the hypothalamic meta-
bolic control output coordinates an appropriate level
of beta cell GSIS that may include increased (normal)
paracrine dopamine activity and peripheral insulin
sensitivity to maintain normal fasting and glucose tol-
erance glucose levels. Such a hypothalamic control sys-
tem may contribute to the hyperbolic relationship of the
“disposition index” that relates level of beta cell GSIS to
insulin sensitivity [48] and we are currently investigating
this possibility.
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hypothalamic-neuroendocrine axis as a composite may in
part contribute to the observed bromocriptine-induced
decrease in hypertension, liver fat content and insulin re-
sistance in these SHR rats as described below.
To appreciate the impact of bromocriptine treatment
on hepatic lipid and glucose metabolism observed in this
study, one must first review the physiological relation-
ship between these liver activities in normal and insulin
resistant states. The physiological relationship between
hepatic lipid and glucose metabolism differs markedly
between insulin sensitive and insulin resistant states
(reviewed in [49]). Under normal physiological condi-
tions, circadian increases in hepatic lipogenesis are gen-
erally coupled to decreases in whole body and hepatic
FFA oxidation and hepatic glucose output typically
synchronized to the fed state or feeding phase of the
day. Contrariwise, circadian decreases in lipogenesis are
coupled to increased whole body and hepatic FFA oxida-
tion and hepatic glucose output during the fasted state or
circadian fasting phase of the day in rodents [2]. Such cir-
cadian organization of these metabolic activities synchro-
nizes the animal with its daily cyclic environment of food
availability and internal locomotor activity rhythm (food
seeking/gathering, feeding/lipogenesis synchronized tem-
porally as are sleeping/fasting/FFA oxidation), thereby en-
hancing survival potential [2]. By comparison, in insulin
resistant states, hepatic lipogenesis, FFA oxidation, and
hepatic glucose output are all simultaneously increased at
their respective circadian peak activity times (reviewed in
[1]). In studies of humans as well, hepatic insulin resist-
ance respecting control of glucose production associates
most often with increased, not decreased, hepatic lipid
synthesis/content and FFA oxidation [50-57]. Although a
variety of genetic manipulations that result in increased
hepatic FFA oxidation have been demonstrated to im-
prove hepatic insulin resistance, primarily by decreasing
hepatic lipid content (e.g., triacylglycerol, diacylglycerol,
acyl-CoA, lysophosphatidic acid, and/or phosphatidic
acid) [58-64], hepatic FFA oxidation is a potent stimulus
for gluconeogenesis, reactive oxygen species generation
(ROS), inflammatory cytokine production and insulin re-
sistance [17,19-22,49-55,57,65,66]. Moreover, reduction of
hepatic FFA oxidation by genetic manipulations that actu-
ally enhance fatty liver is still coupled to improved insulin
sensitivity or glucose tolerance [67-73], reviewed in [49].
In the SHR rat model investigated herein, as in human in-
sulin resistant states such as obesity and fatty liver
[50-55,57], insulin resistance is coupled to increased hep-
atic lipid content, FFA oxidative activity/capacity, and glu-
coneogenic activity/capacity.
In obese, hyperinsulinemic, insulin resistant states such
as the aged SHR rat, increased hepatic fatty acid level
resulting from increased adipose lipolysis and subsequentplasma FFA uptake, dietary fat intake and/or de novo lipo-
genesis can potentiate increased inappropriate hepatic fat
accumulation (e.g., steatosis) and fatty acid oxidation with
ensuing cellular pathological consequences, termed lipo-
toxicity [49,56,65,74-77], reviewed in [78,79]. Lipotoxicity
manifested as excess production of triacylglycerol inter-
mediates (e.g., diacylglycerol, acyl-CoA, lysophosphatidic
acid, phosphatidic acid) at specific and as yet poorly
understood intracellular sites and/or overload in substrate
driven fatty acid oxidation that ultimately results in
incomplete fatty acid oxidation with the generation of
oxidation intermediates (acid soluble intermediates) can
facilitate reactive oxygen species (ROS) production and
subsequent pro-inflammatory protein synthesis such as
NFκB, JNK, and SOCS3 [65,77,80-82]. Such increased fatty
acid oxidation also induces an increase in mitochondrial
tricarboxylic acid cycle activity (though inadequate for the
supply of fatty acids), increased gluconeogenic precursor
generation, and subsequent respiratory dysfunction lead-
ing to increased generation of ROS [4,8-10,50-55,57] that
also stimulate such pro-inflammatory protein synthesis
[55-57,83-86] and stimulate PGC1 and FOXO1 synthesis
[87], transcription factors that potentiate a further in-
creased drive for FFA oxidation and gluconeogenesis
[70,74,87-97]. Increases in hepatocellular levels of ROS
and these pro-inflammatory proteins can also potentiate
insulin resistance respecting insulin inhibition of gluco-
neogenesis and can simultaneously facilitate hepatic lipo-
genesis as more fully discussed below.
Regarding the influence of hepatic NFκB, JNK, and
SOCS3 on gluconeogenesis, increased activity of any of
these proteins can induce increased gluconeogenesis by
inhibiting hepatic insulin signaling [53,80,81,84,98-101]
and either concurrently or independently potentiating
activation of FOXO1α [77,84], a key transcription factor
for the induction of the gluconeogenic enzymes, G6Pase
and PEPCK [93,102] (and for the induction of enzymes
that damage respiratory complexes leading to increased
ROS production and subsequent insulin resistance)
[103]. Increases in JNK transcription can be induced by
incomplete FFA oxidation and ROS production, as de-
scribed above, as well as by local or circulating cytokines
[53,99] and JNK is a strong stimulus for activation of
FOXO1α [84]. Liver FOXO1α activation has been coupled
to the insulin resistant diabetic phenotype [58-64,87,104].
Moreover, hepatic PGC1α, a transcription factor that asso-
ciates with FOXO1α to induce transcription of gluconeo-
genic enzymes, induces hepatic insulin resistance and is
itself elevated in diabetes [89-91,93-96,105]. Increased
PGC1α level is also a strong activator of fatty acid oxida-
tion in liver and this increased activity can function to
maintain the proinflammatory/gluconeogenic state by
providing for excess fat oxidation as described above. In-
creases in hepatic SOCS3, by JNK or other cytokine/
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glucose output by inducing insulin resistance (by inacti-
vating IRS1/2 and/or inducing PGC1α and FOXO1) [106].
Low-level activation of NFκB stimulates the production of
IL-1β, IL-6, and TNFα that can in turn a) stimulate the ac-
tivation and/or synthesis of NFκB, JNK, and SOCS3 and
b) additionally directly inhibit the insulin signaling path-
way [53,80,99,101]. Therefore, simultaneous increases in
NFκB, JNK, and SOCS3 can contribute to a strong and
potentially self-sustaining pro-gluconeogenic/pro FFA oxi-
dative environment.
Activation of NFκB, JNK, and SOCS3 also stimulates
hepatic lipid production. Increases in hepatic JNK (via
IL-6, TNFα, FFA, or oxidative stress) or NFκB can in-
duce SOCS3 transcription that in turn can induce
SREBP1, a potent transcription factor for several lipo-
genic enzymes within the liver [57]. Furthermore, this
activity may be enhanced by PGC1β, a strong coactiva-
tor of SREBP1 to stimulate lipogenic gene expression
[89-91,93-96,107]. Hepatic reduction of JNK or NFκB
[108-110] or suppression of SOCS3 [101] reduces fatty
liver. Additionally, other studies have shown that in-
creases in hepatic ROS level are also a stimulus for
SREBP1 synthesis without effect on insulin signaling
through IRS-1 or AKT [111-114]. Hepatic insulin resist-
ance is also coupled to enhanced liver PPARγ levels that
function to increase lipid synthesis [115-117]. It should
be appreciated that hepatic gene knock-out studies, as op-
posed to suppression studies, for any one of these three
proteins may yield results indicating exacerbation in-
stead of reduction of the hepatic gluconeogenic/lipogenic
phenotype due to overcompensation of redundant pro-
inflammatory pathways [118], however the overwhelming
composite of available evidence indicates that moderate
reductions of elevated levels of these proteins towards the
normal range is coupled to a reduction of the gluconeo-
genic/lipogenic liver phenotype as outlined above. Finally,
another master regulator of hepatic lipogenesis, mTORC1,
not only induces lipogenic activity but can potentiate insu-
lin resistance via stimulation of SOCS3 expression [119],
which can also stimulate lipogenesis via SREBP1 as de-
scribed above. Therefore, moderate and simultaneous in-
creases in hepatic ROS [111-114] and/or NFκB, JNK, and
SOCS3 can interact to facilitate the induction and main-
tenance of a more gluconeogenic/FFA oxidative and lipo-
genic liver via simultaneous induction of the master
activators of lipogenesis (PGC1β, SREBP1, and mTORC)
and gluconeogenesis (FOXO1, PGC1α), concurrently with
induction of FFA-oxidative activity (PGC1α, PPARα), ac-
tivity of which in turn sustains the increase in ROS and
pro-inflammatory protein environment and a vicious cycle
is born. These ROS and proinflammatory proteins may be
induced by a high fat diet (with consequent over-supply of
FFAs to liver) [50-55,57] or by an altered neuroendocrineorganization (e.g., low SCN dopamine and high VMH NE
and 5HT activities) independent of a high fat diet that
re-programs metabolism favoring a liver biochemistry
inducing their production as in the SHR rats held on
a regular (low-fat) diet in this study [1]. This neuroendo-
crine driven hepatic pro-inflammatory state may occur
with even moderately increased antecedent incomplete
FFA oxidation, mitochondrial dysfunction, ER stress and
ROS over-generation.
Although typically viewed as pathology, such an en-
dogenous programmed mechanism for increased hepatic
lipid and glucose production can have substantive sur-
vival benefits for animals in the wild during seasons of
low food availability. During long seasons of low food
(and glucose) supply, a programmed induction of in-
creased hepatic lipogenesis and secretion, coincident
with increased hepatic glucose output, under the setting
of insulin resistance would allow for increased peripheral
utilization of mobilized fat and CNS utilization of (hep-
atic) glucose (that has a predominant requirement for
glucose as a fuel source) and such alterations in metab-
olism would increase odds of organismal survival under
this environmental stress. Our previous work indicates that
the seasonal obese, insulin resistant state, characterized by
increased hepatic lipogenesis and glucose output, can be
manifested by alterations in hypothalamic activities charac-
terized by low dopaminergic tone at the area of the SCN
and increased noradrenergic and serotonergic tone at the
VMH without any alteration in diet [3,4,11,12,14,15] and
timed bromocriptine treatment reverses both this hypo-
thalamic activity and the heightened hepatic lipogenic/
gluconeogenic metabolic state [5,6,8-10,14].
In the present study, bromocriptine decreased abnor-
mally elevated VMH NE and serotonin levels that are
known not only to be associated with insulin resistance
but actually to induce hyperinsulinemia, insulin resist-
ance, glucose intolerance and fatty liver, increased nor-
adrenergic drive to adipose leading to increased lipolysis
(and FFA flux to liver), and increased plasma norepin-
ephrine level potentiating increased gluconeogenesis
[11,12,14,15,120]. Bromocriptine-induced decrease in liver
lipid content resulting from decreased plasma insulin levels
[5,6,10] and present study, decreased hepatic lipogenesis
[6,9] and/or decreased plasma FFA availability [5] may re-
duce over-stimulated fatty acid oxidation and subsequent
incomplete fatty acid oxidation metabolites (acid soluble
metabolites) and by-products (such as ceramides, acyl-
CoAs, diacylglycerol, and lipid peroxides) [50-55,57,78,79]
and subsequent mitochondrial derived ROS [78,79] collect-
ively thereby simultaneously reducing NFκB, JNK, and
SOCS3 levels as observed in this study. Under conditions
of insulin resistance, ablation or elimination of any one
of these 3 pro-inflammatory protein pathways can be
compensated for by up-regulation of the others with
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does not appear to be the case with bromocriptine treat-
ment in this study. Bromocriptine reduced all three pro-
inflammatory protein levels concurrently that resultantly
can act to contribute to the observed bromocriptine-
induced simultaneous reductions in the master activators
of lipogenesis and gluconeogenesis as described above.
The coupled effects of bromocriptine to concomitantly re-
duce liver activated FOXO1 (induced increase in FOXO1-
ser256), G6Pase, and PEPCK levels on the one hand and
SREBP1, mTORC, PPARγ, and PGC1β levels on the other
offer mechanisms by which bromocriptine treatment re-
duced both plasma glucose level and hepatic fat content,
respectively. The effect of bromocriptine to reduce hepatic
gluconeogenic capacity itself may derive in part from its
induced reduction of hepatic FFA oxidative capacity
as assessed by the reduced levels of hepatic PGC1α and
PPARα in bromocriptine-treated animals, levels of which are
elevated in insulin resistant states [50-55,57,89-91,93-96].
In addition to its effects to reduce hepatic PGC1α and
PPARα, bromocriptine-induced decreases in plasma FFA
and liver lipid synthesis may function to reduce liver FFA
oxidative capacity and subsequently to reduce ROS pro-
duction and inflammatory protein(s) synthesis in turn re-
ducing insulin resistance and gluconeogenesis while also
breaking the vicious positive feedback cycle on this path-
way induced by the ROS.
Since bromocriptine can reverse insulin resistance,
glucose intolerance and fattening by its i.c.v. injection,
the present observed effects on hepatic glucose and lipid
metabolism may be the indirect result of its treatment
effects on the entire neuroendocrine axis, not only by in-
fluencing the VMH and SCN as described above and re-
ducing neuropeptide Y and corticotropin levels in the
paraventricular hypothalamus as previously described
[45], and such is the topic of our ongoing investigation.
Such centrally elicited effects of bromocriptine do not
preclude any additional direct peripheral effects of the
therapy to produce the results described herein and such
considerations are the focus of our ongoing investiga-
tion. The bromocriptine effect on liver insulin signaling
pathway proteins and redox status as it relates to its im-
pact on lipogenesis and gluconeogenesis remain as yet
undetermined and the results of this study suggest that
such investigations are warranted. It should be appreci-
ated that while the small reduction in food consumption
with bromocriptine treatment observed in this study
may contribute to its overall effects on metabolic status,
such small reductions (in low fat content food) are not
large enough to explain the large reductions in body fat,
liver fat, insulin resistance, or hypertension, and indeed
previous studies have demonstrated improvements in in-
sulin resistance and body fat of bromocriptine treated
animals without any change in feeding [5,6,10].Respecting neuroendocrine impact on blood pressure
in MS, reductions in hyperleptinemia and elevated plasma
NE can interact to reduce vasoconstriction and hyperten-
sion (reviewed in [1]) and marked improvements in these
plasma parameters and of hypertension were observed fol-
lowing bromocriptine treatment of SHR rats. Moreover,
we have observed a strong hypertensive effect of VMH
NE plus 5HT infusion into the VMH of normal rats [10]
and in the present study bromocriptine treatment reduced
elevated VMH NE and 5HT activities in these SHR rats to
normal levels. Previous studies have likewise documented
an anti-hypertensive effect of bromocriptine in SHR rats
and investigations into mechanisms of this bromocriptine-
induced effect suggest both complex central and periph-
eral actions of the agent to reduce sympathetic tone,
plasma NE level, and vasoconstriction [106,121-127].
In summary, timed bromocriptine treatment reduces
overactive noradrenergic and serotonergic activities at the
VMH of hypertensive, obese, insulin resistant SHR rats,
activities of which have previously been demonstrated to
predispose to insulin resistance, hypertension, and fatten-
ing ([7], reviewed in [1]). This bromocriptine treatment
also reduces hypertension and neuroendocrine stimuli for
hepatic insulin resistance and lipid accumulation, par-
ticularly increased sympathetic drive, hyperinsulinemia,
hyperleptinemia, and reduced plasma adiponectin. Its ef-
fects to reduce liver lipid content and gluconeogenic cap-
acity at the level of the liver are coupled to a reduction of
multiple activated pro-inflammatory protein pathways
that concurrently induce transcriptional master activators
of lipogenesis and gluconeogenesis. Simultaneously, such
bromocriptine treatment also reduces major transcription
factors that increase FFA oxidative capacity of the liver,
which in and of itself may contribute to the drug-induced
reduction in gluconeogenic enzyme levels. Available
evidence suggests that these peripheral effects of bromo-
criptine are likely functionally linked to its impact on hypo-
thalamic, particularly SCN and VMH activities.
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